Results 71 to 80 of about 26,425 (258)
THE RECOMBINANT ANTIGENS FOR VACCINES FOR THE TREATMENT OF PAPILLOMAVIRUS (REVIEW)
Разработка и регистрация лекарственных средств, 2019 Two licensed vaccines Gardasil and Cervarix, containing main capsid protein L1 virus-like particles antigen, are used for prevention of diseases associated with human papilloma virus.
M. A. Zhuchenko
doaj
Biotechnology and Bioengineering, EarlyView.ABSTRACT Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer.
Nicholas Samuelson +5 more
wiley +1 more source
Earth, Planets and Space, 2018 The April 27, 2016 eruption sequence at White Island was comprised of 6 discrete eruptive events that occurred over a 35-min period. Seismicity included three episodes of VLP activity: the first occurring ~ 2 h and a second occurring 10 min prior to the ...
Arthur Jolly +3 more
doaj +1 more source
Biotechnology and Bioengineering, EarlyView.SpyCatcher‐mi3 nanoparticles presenting HKU5, NeoCoV, and HKU5‐CoV‐2 RBD‐SD1 induced strong, cross‐reactive IgG responses in immunized mice. The surrogate virus neutralization test demonstrated strong activity in sera from homologous vaccination. ABSTRACT Recent discoveries of merbecoviruses such as HKU5, NeoCoV, and HKU5‐CoV‐2 that use angiotensin ...
Peter J. Halfmann +11 more
wiley +1 more source
Mannosylation enhances VLP binding and uptake by murine APCs.
, 2014 Murine splenocytes pulsed with DyLight labeled; VLP (white), monomannose-VLP (grey) or dimannose-VLP (black), were incubated at 4°C (B,D,F) or 37°C (C,E,G).
Margaret A. Baird (615879) +4 more
core +1 more source
Biotechnology and Bioengineering, EarlyView.ABSTRACT Plant virus‐like particles (VLPs) are promising nanotechnology platforms, but their translation requires purification strategies suitable for large‐scale production. Here, we developed a nuclease‐free downstream process for Physalis mottle virus (PhMV) VLPs expressed in Escherichia coli, combining ammonium sulfate precipitation, low‐pH ...
Sean K. Hsu +3 more
wiley +1 more source
Particle size distributions of hHPV16 VLP and cHPV16 VLP.
, 2012 The HPV16 VLP populations along with their associated hydrodynamic diameters were analyzed by DLS as described in the Materials and Methods section. Each HPV16 VLP was prepared in 25 mM MOPS containing 75 mM NaCl pH 7.0 and adjusted to 40 µg/ml.
Hye-Lim Kwag (169206) +3 more
core +1 more source
Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality
BMEMat, EarlyView.Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim +9 more
wiley +1 more source
Significance of VLPs in Vlp-circRNA vaccines: a vaccine candidate or delivery vehicle?
RNA BiologyCircular RNAs (circRNAs) are a class of single-stranded RNAs with a closed loop lacking 5' and 3' ends. These circRNAs are translatable and, therefore, have a potential in developing vaccine. CircRNA vaccines have been shown to be more stable, safe, easy to manufacture and scale-up production when compared to mRNA vaccines. However, these vaccines also
Reeshu Gupta +3 more
openaire +3 more sources
Major findings and recent advances in virus-like particle (VLP)-based vaccines. [PDF]
, 2017 Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last three decades. VLPs constitute versatile tools in vaccine development due to their favourable immunological characteristics such as their size, repetitive ...
Mohsen, Mona +11 more
core +1 more source